文献速递前列腺癌

[18F]PARPi PET/CT用于指导PARP抑制剂治疗mCRPC

Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-02-26

该回顾性研究分析了15例接受[18F]PARPi PET/CT后使用PARP抑制剂的mCRPC患者,其中2例存在同源重组修复基因改变。基线骨病灶[18F]PARPi摄取指标与PSA应答百分比相关(r=0.72-0.79,均p<0.05),提示其可能作为疗效预测生物标志物。

要点

  • 基线[18F]PARPi PET骨病灶TBR与PSA应答百分比相关。
  • 无不良事件患者骨病灶TBR高于发生不良事件者(p<0.05)。
  • 结果支持[18F]PARPi PET/CT用于患者选择和疗效监测。

核心结论

  • 基线mCRPC病灶[18F]PARPi摄取与PARP抑制剂治疗的PSA应答相关,骨病灶TBR越高PSA下降越大。

研究设计与样本

  • 回顾性分析15例接受[18F]PARPi PET/CT并后续使用PARP抑制剂的mCRPC患者,其中2例检出同源重组修复基因改变。

主要发现

  • 13例患者[18F]PARPi PET显示骨转移,9例淋巴结转移,3例内脏转移,1例前列腺病灶。
  • 15例中6例PSA下降≥50%,8例下降<50%,1例PSA升高>100%。
  • PSA降至最低值的中位时间为40天(IQR 20-76天)。
  • 骨病灶[18F]PARPi PET平均、峰值和最大TBR与PSA变化百分比相关(r=0.72-0.79,均p<0.05);淋巴结病灶相关性较弱且无统计学意义(r=0.49-0.53,均p>0.05)。
  • 5例因不良事件停药,中位停药时间28天(IQR 27-69天);无不良事件者(n=3)骨病灶TBR高于发生不良事件者(n=12,p<0.05)。

临床怎么用

  • 可考虑将[18F]PARPi PET/CT用于mCRPC患者PARP抑制剂治疗前的筛选和疗效预测。

局限性

  • 回顾性研究,样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Poly ADP-ribose polymerase (PARP) inhibitors have become an important treatment option for metastatic castration-resistant prostate cancer (mCRPC), targeting PARP1-mediated DNA repair. We investigated [18F]PARPi positron emission tomography (PET) uptake as a predictive biomarker of mCRPC. METHODS: We retrospectively analyzed 15 mCRPC patients who underwent [18F]PARPi PET/computed tomography (CT) examinations and were subsequently treated with PARP inhibitors andrs; homologous recombination repair alterations were detected in two patients. Lesions exhibiting uptake above the background were segmented and quantified. Target to background ratios (TBRs) were derived using the abdominal aorta as a blood pool to normalize interpatient biodistribution. Baseline uptake metrics were correlated with the percentage of prostate-specific antigen (PSA) response. KEY FINDINGS AND LIMITATIONS: Most patients presented with osseous metastases (n = 13) on [18F]PARPi PET, followed by nodal (n = 9), visceral (n = 3), and prostatic (n = 1) lesions. During PARP inhibition, of the 15 patients, six achieved a ≥50% PSA decline, eight showed a <50% decline, and one experienced a >100% PSA increase. The median time to PSA nadir was 40 d (interquartile range [IQR] 20-76 d). The percentage of PSA change correlated well with [18F]PARPi PET mean, peak, and maximum TBRs of bone lesions (all r = 0.72-0.79; all p < 0.05), with weaker, nonsignificant correlations for nodal lesions (r = 0.49-0.53; all p > 0.05). Five patients discontinued treatment due to adverse events (AEs) after a median of 28 d (IQR 27-69 d). Patients without AEs (n = 3) exhibited higher bone lesion TBRs than those with AEs (n = 12, p < 0.05). The limitations of this study are its retrospective nature and small sample size. CONCLUSIONS AND CLINICAL IMPLICATIONS: Baseline [18F]PARPi uptake in mCRPC lesions was associated with a PSA response to PARP inhibition. Higher TBRs particularly in bone lesions predicted a greater PSA decline. These findings support [18F]PARPi PET/CT as a promising tool for patient selection and therapy monitoring, warranting prospective trials with histopathological validation and survival endpoints.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ofner H, Einspieler H, Ozenil M, et al. Positron Emission Tomography/Computed Tomography Imaging with [18F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2026. PMID: 41748361. doi:10.1016/j.euo.2026.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。